# A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)

> **NCT02079636** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 142 (actual)

## Conditions studied

- Carcinoma, Non-small Cell Lung

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Pemetrexed
- **DRUG:** Gemcitabine
- **DRUG:** Ramucirumab
- **DRUG:** LY3023414
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02079636
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-28
- **Primary completion:** 2018-05-02
- **Final completion:** 2019-08-29
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2020-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02079636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02079636, "A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02079636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*